Expression patterns of bone morphogenetic protein antagonists in colorectal cancer desmoplastic invasion fronts

Molecular Oncology

Volumn 8, Issue 7, 2014, Pages 1240-1252

  Karagiannis, George S ^a,b   Treacy, Ann ^c   Messenger, David ^b   Grin, Andrea ^a,d   Kirsch, Richard ^a,b   Riddell, Robert H ^a,b   Diamandis, Eleftherios P ^a,b,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c Charlemont Clinic   (Ireland)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Bone morphogenetic protein antagonists; Cancer associated fibroblasts; Colorectal cancer; Follistatin; Gremlin 1; High temperature requirement A3; Tumor budding

Indexed keywords

BONE MORPHOGENETIC PROTEIN; FOLLISTATIN; GREMLIN 1; PROTEIN HTRA3; UNCLASSIFIED DRUG; GREM1 PROTEIN, HUMAN; HTRA3 PROTEIN, HUMAN; SERINE PROTEINASE; SIGNAL PEPTIDE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CELL COMPARTMENTALIZATION; COCULTURE; COLORECTAL CANCER; CONTROLLED STUDY; EPITHELIUM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR INVASION; TUMOR MICROENVIRONMENT; COHORT ANALYSIS; COLON; COLORECTAL TUMOR; FEMALE; MALE; MIDDLE AGED; PATHOLOGY; RECTUM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BONE MORPHOGENETIC PROTEINS; COHORT STUDIES; COLON; COLORECTAL NEOPLASMS; FEMALE; FOLLISTATIN; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; RECTUM; SERINE ENDOPEPTIDASES;

EID: 84908548532     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.04.004     Document Type: Article

References (37)

1. Alarmo E.L., Kallioniemi A. A bone morphogenetic proteins in breast cancer: dual role in tumourigenesis?. Endocr. Relat. Cancer 2010, 17:R123-R139.
2. Altman D.G., McShane L.M., Sauerbrei W., Taube S.E. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. PLoS Med. 2012, 9:e1001216.
3. Barresi V., Reggiani Bonetti L., Branca G., Di Gregorio C., Ponz de Leon M., Tuccari G. Colorectal carcinoma grading by quantifying poorly differentiated cell clusters is more reproducible and provides more robust prognostic information than conventional grading. Virchows Arch. 2012, 461:621-628.
4. Beck S.E., Jung B.H., Fiorino A., Gomez J., Rosario E.D., Cabrera B.L., et al. Bone morphogenetic protein signaling and growth suppression in colon cancer. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 291:G135-G145.
5. Beites C.L., Hollenbeck P.L., Kim J., Lovell-Badge R., Lander A.D., Calof A.L. Follistatin modulates a BMP autoregulatory loop to control the size and patterning of sensory domains in the developing tongue. Development 2009, 136:2187-2197.
6. Bissell M.J., Radisky D. Putting tumours in context. Nat. Rev. Cancer 2001, 1:46-54.
7. Buckowitz A., Knaebel H.P., Benner A., Blaker H., Gebert J., Kienle P., et al. Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases. Br. J. Cancer 2005, 92:1746-1753.
8. Grin A., Messenger D.E., Cook M., O'Connor B.I., Hafezi S., El-Zimaity H., et al. Peritoneal elastic lamina invasion: limitations in its use as a prognostic marker in stage II colorectal cancer. Hum. Pathol. 2013, 44:2696-2705.
9. Karagiannis G.S., Berk A., Dimitromanolakis A., Diamandis E.P. Enrichment map profiling of the cancer invasion front suggests regulation of colorectal cancer progression by the bone morphogenetic protein antagonist, gremlin-1. Mol. Oncol. 2013, 7:826-839.
10. Karagiannis G.S., Pavlou M.P., Diamandis E.P. Cancer secretomics reveal pathophysiological pathways in cancer molecular oncology. Mol. Oncol. 2010, 4:496-510.
11. Karagiannis G.S., Petraki C., Prassas I., Saraon P., Musrap N., Dimitromanolakis A., et al. Proteomic signatures of the desmoplastic invasion front reveal collagen type XII as a marker of myofibroblastic differentiation during colorectal cancer metastasis. Oncotarget 2012, 3:267-285.
12. Karagiannis G.S., Poutahidis T., Erdman S.E., Kirsch R., Riddell R.H., Diamandis E.P. Cancer-associated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressure on cancer tissue. Mol. Cancer Res. 2012, 10:1403-1418.
13. Karagiannis G.S., Schaeffer D.F., Cho C.K., Musrap N., Saraon P., Batruch I., et al. Collective migration of cancer-associated fibroblasts is enhanced by overexpression of tight junction-associated proteins claudin-11 and occludin. Mol. Oncol. 2014, 8:178-195.
14. Karamitopoulou E., Zlobec I., Born D., Kondi-Pafiti A., Lykoudis P., Mellou A., et al. Tumour budding is a strong and independent prognostic factor in pancreatic cancer. Eur. J. Cancer 2012, 49:1032-1039.
15. Kodach L.L., Bleuming S.A., Musler A.R., Peppelenbosch M.P., Hommes D.W., van den Brink G.R., et al. The bone morphogenetic protein pathway is active in human colon adenomas and inactivated in colorectal cancer. Cancer 2008, 112:300-306.
16. Kosinski C., Li V.S., Chan A.S., Zhang J., Ho C., Tsui W.Y., et al. Gene expression patterns of human colon tops and basal crypts and BMP antagonists as intestinal stem cell niche factors. Proc. Natl. Acad. Sci. U S A 2007, 104:15418-15423.
17. Kotzsch A., Nickel J., Seher A., Heinecke K., van Geersdaele L., Herrmann T., et al. Structure analysis of bone morphogenetic protein-2 type I receptor complexes reveals a mechanism of receptor inactivation in juvenile polyposis syndrome. J.Biol. Chem. 2008, 283:5876-5887.
18. Mitola S., Ravelli C., Moroni E., Salvi V., Leali D., Ballmer-Hofer K., et al. Gremlin is a novel agonist of the major proangiogenic receptor VEGFR2. Blood 2010, 116:3677-3680.
19. Mitrovic B., Schaeffer D.F., Riddell R.H., Kirsch R. Tumor budding in colorectal carcinoma: time to take notice. Mod. Pathol. 2012, 25:1315-1325.
20. Namkoong H., Shin S.M., Kim H.K., Ha S.A., Cho G.W., Hur S.Y., et al. The bone morphogenetic protein antagonist gremlin 1 is overexpressed in human cancers and interacts with YWHAH protein. BMC Cancer 2006, 6:74.
21. Pino M.S., Kikuchi H., Zeng M., Herraiz M.T., Sperduti I., Berger D., et al. Epithelial to mesenchymal transition is impaired in colon cancer cells with microsatellite instability. Gastroenterology 2009, 138:1406-1417.
22. Ravelli C., Mitola S., Corsini M., Presta M. Involvement of alphavbeta3 integrin in gremlin-induced angiogenesis. Angiogenesis 2012, 16:235-243.
23. Reddi A.H., Reddi A. Bone morphogenetic proteins (BMPs): from morphogens to metabologens. Cytokine Growth Factor Rev. 2009, 20:341-342.
24. Saaf A.M., Halbleib J.M., Chen X., Yuen S.T., Leung S.Y., Nelson W.J., et al. Parallels between global transcriptional programs of polarizing Caco-2 intestinal epithelial cells invitro and gene expression programs in normal colon and colon cancer. Mol. Biol. Cell 2007, 18:4245-4260.
25. Sasaki S., Masaki T., Umetani N., Shinozaki M., Yokoyama T., Ono M., et al. Microsatellite instability is associated with the macroscopic configuration of neoplasms in patients with multiple colorectal adenomas. Jpn. J. Clin. Oncol. 1998, 28:427-430.
26. Shia J., Ellis N.A., Paty P.B., Nash G.M., Qin J., Offit K., et al. Value of histopathology in predicting microsatellite instability in hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer. Am. J. Surg. Pathol. 2003, 27:1407-1417.
27. Singh A., Morris R.J. The Yin and Yang of bone morphogenetic proteins in cancer. Cytokine Growth Factor Rev. 2010, 21:299-313.
28. Sneddon J.B. The contribution of niche-derived factors to the regulation of cancer cells. Methods Mol. Biol. 2009, 568:217-232.
29. Sneddon J.B., Zhen H.H., Montgomery K., van de Rijn M., Tward A.D., West R., et al. Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation. Proc. Natl. Acad. Sci. U S A 2006, 103:14842-14847.
30. Tocharus J., Tsuchiya A., Kajikawa M., Ueta Y., Oka C., Kawaichi M. Developmentally regulated expression of mouse HtrA3 and its role as an inhibitor of TGF-beta signaling. Dev. Growth Differ 2004, 46:257-274.
31. Wang L.M., Kevans D., Mulcahy H., O'Sullivan J., Fennelly D., Hyland J., et al. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am. J. Surg. Pathol. 2009, 33:134-141.
32. Warusavitarne J., McDougall F., de Silva K., Barnetson R., Messina M., Robinson B.G., et al. Restoring TGFbeta function in microsatellite unstable (MSI-H) colorectal cancer reduces tumourigenicity but increases metastasis formation. Int. J. Colorectal Dis. 2009, 24:139-144.
33. Wen X.Z., Akiyama Y., Baylin S.B., Yuasa Y. Frequent epigenetic silencing of the bone morphogenetic protein 2 gene through methylation in gastric carcinomas. Oncogene 2006, 25:2666-2673.
34. Wright C.L., Stewart I.D. Histopathology and mismatch repair status of 458 consecutive colorectal carcinomas. Am. J. Surg. Pathol. 2003, 27:1393-1406.
35. Zeisberg M., Hanai J., Sugimoto H., Mammoto T., Charytan D., Strutz F., et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat. Med. 2003, 9:964-968.
36. Zlobec I., Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget 2011, 1:651-661.
37. Zlobec I., Lugli A. Invasive front of colorectal cancer: dynamic interface of pro-/anti-tumor factors. World J. Gastroenterol. 2009, 15:5898-5906.